344 related articles for article (PubMed ID: 36289168)
21. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
Front Immunol; 2022; 13():827306. PubMed ID: 35173736
[TBL] [Abstract][Full Text] [Related]
22. Alternative strategies to increase the immunogenicity of COVID-19 vaccines in kidney transplant recipients not responding to two or three doses of an mRNA vaccine (RECOVAC): a randomised clinical trial.
Kho MML; Messchendorp AL; Frölke SC; Imhof C; Koomen VJ; Malahe SRK; Vart P; Geers D; de Vries RD; GeurtsvanKessel CH; Baan CC; van der Molen RG; Diavatopoulos DA; Remmerswaal EBM; van Baarle D; van Binnendijk R; den Hartog G; de Vries APJ; Gansevoort RT; Bemelman FJ; Reinders MEJ; Sanders JF; Hilbrands LB;
Lancet Infect Dis; 2023 Mar; 23(3):307-319. PubMed ID: 36354032
[TBL] [Abstract][Full Text] [Related]
23. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study.
Hillus D; Schwarz T; Tober-Lau P; Vanshylla K; Hastor H; Thibeault C; Jentzsch S; Helbig ET; Lippert LJ; Tscheak P; Schmidt ML; Riege J; Solarek A; von Kalle C; Dang-Heine C; Gruell H; Kopankiewicz P; Suttorp N; Drosten C; Bias H; Seybold J; ; Klein F; Kurth F; Corman VM; Sander LE
Lancet Respir Med; 2021 Nov; 9(11):1255-1265. PubMed ID: 34391547
[TBL] [Abstract][Full Text] [Related]
24. Immune Response after the Fourth Dose of SARS-CoV-2 mRNA Vaccine Compared to Natural Infection in Three Doses' Vaccinated Solid Organ Transplant Recipients.
Busà R; Russelli G; Miele M; Sorrentino MC; Di Bella M; Timoneri F; Di Mento G; Mularoni A; Vitulo P; Conaldi PG; Bulati M
Viruses; 2022 Oct; 14(10):. PubMed ID: 36298854
[TBL] [Abstract][Full Text] [Related]
25. Mycophenolate mofetil decreases humoral responses to three doses of SARS-CoV-2 vaccine in liver transplant recipients.
Meunier L; Sanavio M; Dumortier J; Meszaros M; Faure S; Ursic Bedoya J; Echenne M; Boillot O; Debourdeau A; Pageaux GP
Liver Int; 2022 Aug; 42(8):1872-1878. PubMed ID: 35338550
[TBL] [Abstract][Full Text] [Related]
26. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ
Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185
[TBL] [Abstract][Full Text] [Related]
27. Cellular and humoral immune responses after a third dose of SARS-CoV-2 mRNA vaccine in lung transplant recipients in Japan.
Ui M; Hirama T; Akiba M; Honda M; Kikuchi T; Okada Y
Vaccine; 2023 Jul; 41(31):4534-4540. PubMed ID: 37328349
[TBL] [Abstract][Full Text] [Related]
28. Infection or a third dose of mRNA vaccine elicits neutralizing antibody responses against SARS-CoV-2 in kidney transplant recipients.
Charmetant X; Espi M; Benotmane I; Barateau V; Heibel F; Buron F; Gautier-Vargas G; Delafosse M; Perrin P; Koenig A; Cognard N; Levi C; Gallais F; Manière L; Rossolillo P; Soulier E; Pierre F; Ovize A; Morelon E; Defrance T; Fafi-Kremer S; Caillard S; Thaunat O
Sci Transl Med; 2022 Mar; 14(636):eabl6141. PubMed ID: 35103481
[TBL] [Abstract][Full Text] [Related]
29. Vaccination Against SARS-CoV-2 in Lung Transplant Recipients: Immunogenicity, Efficacy and Safety.
Svorcova M; Novysedlak R; Lischke R; Vachtenheim J; Strizova Z
Front Immunol; 2022; 13():906225. PubMed ID: 35720376
[TBL] [Abstract][Full Text] [Related]
30. Early humoral immune response to two doses of severe acute respiratory syndrome coronavirus 2 vaccine in a diverse group of solid organ transplant candidates and recipients.
Huang HJ; Yi SG; Mobley CM; Saharia A; Bhimaraj A; Moore LW; Kloc M; Adrogue HE; Graviss EA; Nguyen DT; Eagar TN; Jones SL; Ankoma-Sey V; MacGillivray TE; Knight RJ; Gaber AO; Ghobrial RM
Clin Transplant; 2022 May; 36(5):e14600. PubMed ID: 35083796
[TBL] [Abstract][Full Text] [Related]
31. Safety and Reactogenicity of 2 Doses of SARS-CoV-2 Vaccination in Solid Organ Transplant Recipients.
Ou MT; Boyarsky BJ; Motter JD; Greenberg RS; Teles AT; Ruddy JA; Krach MR; Jain VS; Werbel WA; Avery RK; Massie AB; Segev DL; Garonzik-Wang JM
Transplantation; 2021 Oct; 105(10):2170-2174. PubMed ID: 33859151
[TBL] [Abstract][Full Text] [Related]
32. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.
Munro APS; Feng S; Janani L; Cornelius V; Aley PK; Babbage G; Baxter D; Bula M; Cathie K; Chatterjee K; Dodd K; Enever Y; Qureshi E; Goodman AL; Green CA; Harndahl L; Haughney J; Hicks A; van der Klaauw AA; Kanji N; Libri V; Llewelyn MJ; McGregor AC; Maallah M; Minassian AM; Moore P; Mughal M; Mujadidi YF; Holliday K; Osanlou O; Osanlou R; Owens DR; Pacurar M; Palfreeman A; Pan D; Rampling T; Regan K; Saich S; Bawa T; Saralaya D; Sharma S; Sheridan R; Thomson EC; Todd S; Twelves C; Read RC; Charlton S; Hallis B; Ramsay M; Andrews N; Lambe T; Nguyen-Van-Tam JS; Snape MD; Liu X; Faust SN;
Lancet Infect Dis; 2022 Aug; 22(8):1131-1141. PubMed ID: 35550261
[TBL] [Abstract][Full Text] [Related]
33. Humoral Response to the Third Dose of Sars-Cov-2 Vaccine in Kidney Transplant Recipients.
Grupper A; Rabinowich L; Ben-Yehoyada M; Katchman E; Baruch R; Freund T; Hagin D; Shlomo SB; Schwartz D; Schwartz IF; Shashar M; Bassat OK; Halperin T; Turner D; Saiag E; Goykhman Y; Shibolet O; Levy S; Houri I; Katchman H
Transplant Proc; 2022; 54(6):1439-1445. PubMed ID: 35346486
[TBL] [Abstract][Full Text] [Related]
34. Immunogenicity and Safety of the BNT162b2 COVID-19 Vaccine in Patients with Cystic Fibrosis with or without Lung Transplantation.
Lucca F; Bezzerri V; Danese E; Olioso D; Peserico D; Boni C; Cucchetto G; Montagnana M; Tridello G; Meneghelli I; Ros M; Lippi G; Cipolli M
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674422
[TBL] [Abstract][Full Text] [Related]
35. Seroconversion after SARS-CoV-2 vaccination is protective against severe COVID-19 disease in heart transplant recipients.
Kugler S; Vári DK; Veres DS; Király Á; Teszák T; Parázs N; Tarjányi Z; Drobni Z; Szakál-Tóth Z; Prinz G; Miheller P; Merkely B; Sax B
Immun Inflamm Dis; 2023 Nov; 11(11):e1086. PubMed ID: 38018598
[TBL] [Abstract][Full Text] [Related]
36. Comparison of Humoral Response in Kidney Transplant Recipients and Donors and Healthy Volunteers Following Second Dose of SARS-CoV-2 mRNA Vaccine.
Sasaki H; Hasegawa K; Harada H; Takamoto D; Takada Y; Hirano T; Tanabe T; Tanaka H; Miura M
Transplant Proc; 2023 Apr; 55(3):514-520. PubMed ID: 36948961
[TBL] [Abstract][Full Text] [Related]
37. COVID-19 After Vaccination in Lung Transplant Recipients: Real-Life Data.
Türkkan S; Çelik Başaran F; Şahin MF; Beyoğlu MA; Yılmaz E; Yazıcıoğlu A; Yiğit Özay H; Bindal M; Tezer Tekçe Y; Yekeler E
Exp Clin Transplant; 2023 Mar; 21(3):265-271. PubMed ID: 35867010
[TBL] [Abstract][Full Text] [Related]
38. Comparison of the safety and immunogenicity of the BNT-162b2 vaccine and the ChAdOx1 vaccine for solid organ transplant recipients: a prospective study.
Ajlan AA; Ali T; Aleid H; Almeshari K; DeVol E; Alkaff MA; Fajji L; Alali A; Halabi D; Althuwaidi S; Alghamdi S; Ullah A; Alrajhi A; Bzeizi K; Almaghrabi R; Marquez KAH; Elmikkaoui B; Albogumi E; Aldakhil H; Al-Awwami M; Broering DC
BMC Infect Dis; 2022 Oct; 22(1):786. PubMed ID: 36229772
[TBL] [Abstract][Full Text] [Related]
39. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.
Liu X; Shaw RH; Stuart ASV; Greenland M; Aley PK; Andrews NJ; Cameron JC; Charlton S; Clutterbuck EA; Collins AM; Dinesh T; England A; Faust SN; Ferreira DM; Finn A; Green CA; Hallis B; Heath PT; Hill H; Lambe T; Lazarus R; Libri V; Long F; Mujadidi YF; Plested EL; Provstgaard-Morys S; Ramasamy MN; Ramsay M; Read RC; Robinson H; Singh N; Turner DPJ; Turner PJ; Walker LL; White R; Nguyen-Van-Tam JS; Snape MD;
Lancet; 2021 Sep; 398(10303):856-869. PubMed ID: 34370971
[TBL] [Abstract][Full Text] [Related]
40. Development of donor specific antibodies after SARS-CoV-2 vaccination in kidney and heart transplant recipients.
McCune TR; Bray RA; Baran DA; Toepp AJ; Forte SJ; Gilgannon LT; Williams T; Chen S; Sadr H; Gebel HM; Herre JM
Transpl Immunol; 2022 Dec; 75():101722. PubMed ID: 36152939
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
